Drug May Slow Conversion to Definite MS From Clinically Isolated Syndrome
Aubagio may cause delays in conversion to clinical definite MS by slowing the loss of cortical grey matter.
ECTRIMS 2017
Switch to Alemtuzumab Reduces MS Disease Activity
Patients experienced reduced disease activity when switched to alemtuzumab.
Disability Progression Slowed in Relapsing MS With Ocrelizumab Treatment
Data show superiority of OCREVUS compared to Rebif in reducing disability progression independent of relapse activity in people with RMS.
Novel Multiple Sclerosis Drug Shows Promise
Celgene announced new Phase 3 data evaluating the safety and efficacy of ozanimod vs Avonex for RMS.
Fingolimod Promising for Pediatric Relapsing Multiple Sclerosis
There are no FDA-approved MS therapies for the pediatric population.
Comorbidities May Increase Relapse Risk in Multiple Sclerosis
An emerging line of inquiry suggests a potential association between comorbidities and MS relapses, but studies have been limited.
OSA Screening Advised for Fatigued Patients With MS
Patients with multiple sclerosis who experience severe fatigue should be screened for obstructive sleep apnea.
Multiple Sclerosis Lesion Location Linked to Hyperalgesia, Hypoalgesia
In patients with multiple sclerosis, lesions in the right dorsolateral prefrontal cortex may be associated with hypoalgesia, and lesions in the posterior periventricular area, with hyperalgesia.
Earlier Onset of Multiple Sclerosis Linked to Cesarean Delivery, Artificial Lactation
Researchers believe that environmental factors may impact disease severity characteristics in genetically susceptible populations.
Detecting Cognitive Decline in Multiple Sclerosis With Shortened BICAMS
With its 20-minute application time, the BICAMS is one of the few tools available for small centers with only a few staff members who might not be trained in administering neuropsychological tests.
Want to read more?
Please login or register first to view this content.
Next post in ECTRIMS 2017
